TL;DR
This study reveals that Li-Fraumeni Syndrome (LFS), a hereditary cancer predisposition disorder, is more complex than previously thought, often involving multiple genetic and epigenetic events beyond the well-known TP53 gene. By analyzing whole-genome sequencing and methylation data from a large LFS cohort, researchers identified novel genetic modifiers and epigenetic signatures that contribute to cancer risk and variability, paving the way for more personalized risk assessment and management.
What Problem Does This Paper Address?
Li-Fraumeni Syndrome (LFS) is a classic example of an autosomal dominant cancer predisposition disorder, primarily linked to pathogenic germline variants in the TP53 tumor suppressor gene. However, a significant portion of LFS patients (around 30%) do not have a TP53 variant, and even among those who do, about 20% remain cancer-free. This incomplete penetrance and the wide spectrum of associated cancers highlight that TP53 alone doesn't fully explain LFS. The challenge has been to understand the genetic and epigenetic factors that contribute to this phenotypic variability, leading to the development of different cancers at different ages, or even no cancer at all, in individuals with LFS. This paper aims to unravel these additional genomic and epigenomic contributors to LFS.
Methods
The researchers employed a multi-pronged approach:
- Whole-Genome Sequencing (WGS): They performed WGS on a large cohort of LFS patients (n=396) and their family members. This allowed for the identification of single-nucleotide variants (SNVs), insertions/deletions (indels), and structural variants (SVs) across the entire genome.
- DNA Methylation Profiling: Methylation data was collected from peripheral blood leukocytes (PBL) of LFS patients. This technique helps identify epigenetic modifications that can influence gene expression without altering the DNA sequence itself.
- Tiered Gene Prioritization: To manage the vast amount of genomic data, genes were categorized into four tiers based on their known cancer predisposition potential, from highly established autosomal dominant cancer predisposition genes (Tier 1) to all other genes in the genome (Tier 4).
- Cancer Variant Classification Schema: A five-class system was used to classify identified variants based on their pathogenicity (e.g., pathogenic, likely pathogenic) and the gene's role in cancer.
- Epigenome-Wide Association Study (EWAS): This was used to identify methylation probes significantly associated with cancer status.
- cis-Cancer-Associated Secondary Constitutional Epimutations (cis-CSCE): This novel approach identified inherited SNPs in cis with methylation marks associated with cancer, suggesting epigenetic regulation influenced by genetic variants.
- Machine Learning Model: A random forest model was built using cis-CSCE data to predict cancer risk in LFS patients.
- Pathway Analysis: This was used to understand the biological pathways affected by the identified genetic and epigenetic alterations.
Datasets
- LFS Cohort: A large, multi-institutional cohort of 396 individuals meeting LFS clinical criteria, including 374 with pathogenic TP53 variants and 22 with wildtype TP53.
- 1000 Genomes Project (1kGP): Used as a control dataset for germline variant analysis (n=2,504).
- SickKids Cancer Sequencing (KiCS) Program: Used as a control cohort of individuals with cancer but without a known germline TP53 variant (n=185).
- Methylation Data: Collected from PBLs of 359 LFS patients with TP53 variants, with discovery, internal, and external validation cohorts.
- Plasma cfDNA and Tumor Samples: Used for methylation analysis of LEF1.
- The Cancer Genome Atlas (TCGA): Used for comparative analysis of LEF1 methylation in adult tumors.
Key Insights and Ideas
- Beyond TP53: The study strongly reinforces that LFS is not solely a TP53-driven disease. Many patients, especially those without a TP53 variant, have other germline genetic aberrations that predispose them to cancer.
- The Power of Epigenetics: Inherited epigenetic modifications (epimutations) play a significant role in LFS, influencing cancer risk independently of or in conjunction with genetic variants. This opens up a new avenue for understanding disease heterogeneity.
- WNT Pathway as a Protective Factor: Variants in the WNT signaling pathway appear to be associated with decreased cancer incidence and improved survival in TP53 variant carriers, suggesting a protective role. This is a counterintuitive but crucial finding.
- LEF1 Methylation as a Risk Indicator: Hypermethylation of LEF1 in PBLs and plasma cfDNA is linked to increased cancer risk in LFS patients with TP53 variants, offering a potential biomarker.
- Holistic View of Cancer Syndromes: The findings advocate for a shift from viewing hereditary cancer syndromes as single-gene disorders to a more complex, multifactorial perspective that includes multiple genetic and epigenetic contributors.
Key Results
- Alternative Genetic Aberrations: In 8 out of 14 wildtype TP53 carriers who developed cancer, alternative cancer-associated genetic aberrations were identified.
- Secondary Germline Variants: Among TP53 variant carriers who developed cancer, 19 out of 49 harbored a pathogenic variant in another cancer gene.
- WNT Pathway Association: Variants in the WNT signaling pathway were found in 23% of cancer-free TP53 variant carriers compared to 2% of those who developed cancer.
- Epimutation Model Performance: A machine learning model built on cis-CSCE data achieved an AUROC of 0.725 (0.633-0.810) for predicting cancer risk in LFS patients.
- Survival Differences: Three distinct epimutation clusters were identified, with significant differences in survival probability between them (P = 0.0044).
- LEF1 Methylation: Probands almost universally exhibited higher LEF1 methylation than their unaffected family members.
Limitations and Future Work
- Validation of Novel Variants: The clinical significance of variants identified in novel candidate cancer genes (Class 4) and disease-segregating VUSs (Class 5) requires experimental validation.
- Chemotherapy Effects on Methylation: While efforts were made to control for confounding factors, the potential impact of chemotherapy on PBL methylation remains a consideration, and further prospective studies are needed.
- Limited Validation Cohort for Combined Data: The authors note that it's difficult to discern the complementarity of P/LP variants and epimutations without an additional validation cohort with both WGS and methylation data.
- Future Directions: The study emphasizes the need for comprehensive, genome-wide germline molecular profiling for LFS patients to enable personalized surveillance and treatment strategies. It also calls for a broader understanding of hereditary cancer syndromes beyond single genes.
Summary updated